SUNRISE, Fla., April 11, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that it has been named a 2012 finalist in the Bioscience company category for the Greater Miami Chamber of Commerce Technology Leaders of the Year award which highlights individuals and organizations with extraordinary technological hands-on experience whose management of technology resources and/or technological innovations have made outstanding contributions to their organization and the community.
"We are honored to receive this recognition and acknowledgement of the contribution that Bioheart has made to date in the cardiovascular community," said Mike Tomas, Bioheart's President and CEO. "From the success of its clinical trials, Bioheart is well poised to bring its products to market in the foreseeable future."
This prestigious awards program honors professionals who have distinguished themselves within the technology profession and/or community, and brings together the entire South Florida technology industry for a celebration with unprecedented networking opportunities. The 2012 Technology Leader of the Year award recipients will be honored at a luncheon reception on Friday, April 27, 2012 at Jungle Island Tree Top Ballroom in Miami, when the winners in each of the award categories will be announced.
The Greater Miami Chamber of Commerce is the voice of business in South Florida, representing more than 400,000 employees of member companies. Greater Miami is a proactive Chamber, regularly getting engaged in issues important to its member companies and individuals. For more information, visit www.miamichamber.com.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.